Our Company l News & Events

Ikonisys to Present at the Thomas Weisel Partners Healthcare Conference 2009

New Haven, Conn., September 2, 2009:

Ikonisys announced today that Dr. Petros Tsipouras, Chairman and Chief Executive Officer, will present at the Thomas Weisel Partners Healthcare Conference 2009.

Presentation details are as follows:

Date: Friday, September 11, 2009

Time: 10:55am Eastern Daylight Time

Location: The Four Seasons Hotel, Boston, MA

About Ikonisys
Founded in 1999, Ikonisys, Inc. is a privately-held, next-generation diagnostic company specializing in non-invasive, cell-based diagnostics. Ikonisys has developed the CellOptics® platform, a robotic microscopy technology for full-automated, high-throughput identification and analysis of rare cells by fluorescence in-situ hybridization (FISH).

A pipeline of applications is being developed for cancer diagnosis and management (oncoFISH®) and a non-invasive prenatal screening test for Down Syndrome (fastFISH®) to be run on the Ikoniscope® using the CellOptics technology.  Ikonisys has developed a novel approach for the enrichment, identification and characterization of circulating tumor cells (CTCs).

Ikonisys' first proprietary test, oncoFISH® cervical, is offered as a Laboratory Developed Test through the Company's CAP-accredited clinical laboratory. In addition to oncoFISH cervical, the Company offers three FDA-cleared applications that automate certain commercially available FISH tests.

Media Contact:
Alex Salvi
Renee Viola

Investor Relations Contact:
Louise Mawhinney